Pathogenesis and New Therapeutic Drugs of Alzheimer Disease
WANG Qi-qiong1,2, LÜ Jun-ling1, HU Yong-chuan1, LIU Lei1*
1. Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, Beijing 100730, China; 2. Department of Pharmacy Administration ＆ Clinical Pharmacy,School of Pharmaceutical Science,Peking University,Beijing 100191, China
Abstract：Alzheimer's disease (AD) is a neurodegenerative disease. Pathologic hallmarks of AD include senile plaques comprising β-amyloid (Aβ) proteins along with many other misfolded proteins and neurofibrillary tangles formed by hyperphosphorylated tau protein aggregates. The exact pathogenesis of AD has not yet been clarified, and there are still no methods or drugs to cure AD worldwide. The development progress of AD treatment drugs is slow. Anti-Aβ and anti-Tau proteins are the main direction of research and development, and multiple directions coexist, such as anti-inflammation, improving metabolism and vascular function, and combination therapy. This article reviews the research progress of the pathogenic mechanism and therapeutic drugs of AD.
王其琼, 吕俊玲, 胡咏川, 刘蕾. 阿尔茨海默病致病机制及治疗药物研究新进展[J]. 中国药学杂志, 2020, 55(23): 1939-1947.
WANG Qi-qiong, LÜ Jun-ling, HU Yong-chuan, LIU Lei. Pathogenesis and New Therapeutic Drugs of Alzheimer Disease. Chinese Pharmaceutical Journal, 2020, 55(23): 1939-1947.
KOLAJ I, IMINDU LIYANAGE S, WEAVER D F. Phenylpropanoids and Alzheimer's disease: a potential therapeutic platform[J]. Neurochem Int, 2018, 120: 99-111.
[2]
BLENNOW K, DE LEON M J, ZETTERBERG H. Alzheimer's disease[J]. Lancet, 2006, 368(9533): 387-403.
[3]
PATTERSON C. World Alzheimer report 2018: The state of the art of dementia research:New frontiers[EB/OL]. Alzheimer Disease International, 2018. [2020-03-10]. https://www.alz.co.uk/research/world-report-2018.
[4]
FROZZA R L, LOURENCO M V, DE FELICE F G. Challenges for Alzheimer's disease therapy: insights from novel mechanisms beyond memory defects[J]. Front Neurosci, 2018, 12: 37.
[5]
SELKOE D J, HARDY J. The amyloid hypothesis of Alzheimer's disease at 25 years[J]. EMBO Mol Med, 2016, 8(6): 595-608.
[6]
PANZA F, LOZUPONE M, LOGROSCINO G, et al. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease[J]. Nat Rev Neurol, 2019, 15(2): 73-88.
[7]
DONG Y, LI X, CHENG J, et al. Drug development for alzheimer's disease: microglia induced neuroinflammation as a target?[J]. Int J Mol Sci, 2019, 20(3):558.
[8]
MCCAULLEY M E, GRUSH K A. Alzheimer's disease: exploring the role of inflammation and implications for treatment[J]. Int J Alzheimers Dis, 2015, 2015: 515248.
[9]
TAKEDA S. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors[J]. Neurosci Res, 2019, 141: 36-42.
[10]
MEDINA M, AVILA J. The role of extracellular Tau in the spreading of neurofibrillary pathology[J]. Front Cell Neurosci, 2014, 8: 113.
[11]
HAMPEL H, MESULAM M M, CUELLO A C, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease[J]. Brain, 2018, 141(7): 1917-1933.
[12]
GEMMA C, VILA J, BACHSTETTER A, et al. Brain aging: Models, methods, and mechanisms [M/OL]. Taylor & Francis Group, LLC.2007: Chapter 15. [2020-03-20]. https://www.ncbi.nlm.nih.gov/books/NBK3869/.
[13]
BENDLIN B B. Antidiabetic therapies and Alzheimer disease[J]. Dialogues Clin Neurosci, 2019, 21(1): 83-91.
[14]
GRIZZANTI J, CORRIGAN R, SERVIZI S, et al. Amylin signaling in diabetes and Alzheimer's disease: therapy or pathology?[J]. J Neurol Neuromed, 2019, 4(1): 12-16.
[15]
LEIBSON C L, ROCCA W A, HANSON V A, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study[J]. Am J Epidemiol, 1997, 145(4): 301-308.
[16]
ZHANG J, CHEN C, HUA S, et al. An updated Meta-analysis of cohort studies: diabetes and risk of Alzheimer's disease[J]. Diabetes Res Clin Pract, 2017, 124: 41-47.
[17]
SEBASTIAO I, CANDEIAS E, SANTOS M S, et al. Insulin as a bridge between type 2 diabetes and Alzheimer disease-how anti-diabetics could be a solution for dementia[J]. Front Endocrinol (Lausanne), 2014, 5: 110.
[18]
DE LA MONTE S M. Type 3 diabetes is sporadic Alzheimers disease: mini-review[J]. Eur Neuropsychopharmacol, 2014, 24(12): 1954-1960.
[19]
HARA Y, MCKEEHAN N, FILLIT H M. Translating the biology of aging into novel therapeutics for Alzheimer disease[J]. Neurology, 2019, 92(2): 84-93.
[20]
IADECOLA C. The pathobiology of vascular dementia[J]. Neuron, 2013, 80(4): 844-866.
[21]
HACHINSKI V, GANTEN D, LACKLAND D, et al. Implementing the proclamation of stroke and potentially preventable dementias[J]. Int J Stroke, 2018, 13(8): 780-786.
[22]
IADECOLA C, DUERING M, HACHINSKI V, et al. Vascular cognitive impairment and dementia: JACC scientific expert panel[J]. J Am Coll Cardiol, 2019, 73(25): 3326-3344.
[23]
CUMMINGS J, MORSTORF T, LEE G. Alzheimer's drug-development pipeline: 2016[J]. Alzheimers Dement, 2016, 2(4): 222-232.
[24]
CUMMINGS J, LEE G, MORTSDORF T, et al. Alzheimer's disease drug development pipeline: 2017[J]. Alzheimers Dement, 2017, 3(3): 367-384.
[25]
CUMMINGS J, LEE G, RITTER A, et al. Alzheimer's disease drug development pipeline: 2018[J]. Alzheimers Dement, 2018, 4: 195-214.
[26]
CUMMINGS J, LEE G, RITTER A, et al. Alzheimer's disease drug development pipeline: 2019[J]. Alzheimers Dement, 2019, 5: 272-293.
[27]
KLEIN G, DELMAR P, VOYLE N, et al. Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis[J]. Alzheimers Res Ther, 2019, 11(1): 101.
[28]
OSTROWITZKI S, LASSER R A, DORFLINGER E, et al. A phase Ⅲ randomized trial of gantenerumab in prodromal Alzheimer's disease[J]. Alzheimers Res Ther, 2017, 9(1): 95.
[29]
ANDJELKOVIC M, ABI-SAAB D, DELMAR P, et al. Update on the safety and tolerability of gantenerumab in the ongoing open-label extension of the SCarlet RoAD study in patients with prodromal Alzheimer's disease after approximately 2 years of study duration[J]. Alzheimers Dement, 2018, 14(7s): 241-242.
[30]
LOGOVINSKY V, SATLIN A, LAI R, et al. Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective Abeta antibody[J]. Alzheimers Res Ther, 2016, 8(1): 14.
[31]
LOUREIRO J C, PAIS M V, STELLA F, et al. Passive antiamyloid immunotherapy for Alzheimer's disease[J]. Curr Opin Psychiatry, 2020, 33(3): 284-291.
[32]
SEVIGNY J, CHIAO P, BUSSIERE T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease[J]. Nature, 2016, 537(7618): 50-56.
[33]
HONIG L S, VELLAS B, WOODWARD M, et al. Trial of solanezumab for mild dementia due to Alzheimer's disease[J]. N Engl J Med, 2018, 378(4): 321-330.
[34]
Lilly announces topline results for solanezumab from the dominantly inherited alzheimer network trials unit (DIAN-TU) study: Study with novel trial design did not meet primary endpoint[N/OL]. PR Newswire. 2020-02-10. [2020-03-20]. https://search.proquest.com/docview/2352516497?accountid=13151.
[35]
WIESSNER C, WIEDERHOLD K H, TISSOT A C, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects[J]. J Neurosci, 2011, 31(25): 9323-9331.
[36]
FARLOW M R, ANDREASEN N, RIVIERE M E, et al. Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer's disease[J]. Alzheimers Res Ther, 2015, 7(1): 23.
[37]
VANDENBERGHE R, RIVIERE M E, CAPUTO A, et al. Active Abeta immunotherapy CAD106 in Alzheimer's disease: a phase 2b study[J]. Alzheimers Dement, 2017, 3(1): 10-22.
[38]
NOZOMI H, SANAE Y, MICHIWO K, et al. Elenbecestat, a novel bace inhibitor, demonstrates similar pharmacokinetics and tolerability in Japanese subjects with multiple dosings[J]. Alzheimers Dement, 2018, 14(7s): 1623-1623.
[39]
HENLEY D, RAGHAVAN N, SPERLING R, et al. Preliminary results of a trial of atabecestat in preclinical alzheimer's disease[J]. N Engl J Med, 2019, 380(15): 1483-1485.
[40]
EGAN M F, KOST J, TARIOT P N, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease[J]. N Engl J Med, 2018, 378(18): 1691-1703.
[41]
WESSELS A M, TARIOT P N, ZIMMER J A, et al. Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials[J]. JAMA Neurol, 2019, 77(2):1-11.
[42]
MOUSSA-PACHA N M, ABDIN S M, OMAR H A, et al. BACE1 inhibitors: current status and future directions in treating Alzheimer's disease[J]. Med Res Rev, 2020, 40(1): 339-384.
[43]
NEUMANN U, UFER M, JACOBSON L H, et al. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease[J]. EMBO Mol Med, 2018, 10(11): e9316.
[44]
SMITH A. Another Alzheimer's setback as amgen, novartis abandon bace inhibitor trial-pharmatimes[EB/OL]. PharmaTimes, 2019 [2020-03-10]. http://www.pharmatimes.com/news/another_alzheimers_setback_as_amgen,_novartis_abandon_bace_inhibitor_trial_1294456.
[45]
NOVAK P, ZILKA N, ZILKOVA M, et al. AADvac1, an active immunotherapy for Alzheimer's disease and non alzheimer tauopathies: an overview of preclinical and clinical development[J]. J Prev Alzheimers Dis, 2019, 6(1): 63-69.
[46]
NOVAK P, SCHMIDT R, KONTSEKOVA E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial[J]. Lancet Neurol, 2017, 16(2): 123-134.
[47]
NOVAK P, SCHMIDT R, KONTSEKOVA E, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease[J]. Alzheimers Res Ther, 2018, 10(1): 108.
[48]
Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020: AADvac1 has a disease-modifying effect on Alzheimer's Disease, evidenced by a combination of several biomarkers and clinical outcomes, most pronounced among younger patients[N/OL]. PR Newswire. 2020-04-03. [2020-04-28]. https://search.proquest.com/docview/2385599763?accountid=13151&pq-origsite=summon.
[49]
WEST T, HU Y, VERGHESE P B, et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-Tau antibody, for treatment of Alzheimer's disease and other tauopathies[J]. J Prev Alzheimers Dis, 2017, 4(4): 236-241.
[50]
HANA FLORIAN, KUMAR BUDUR, DELI WANG, et al. ABBV-8E12, a humanized anti-tau monoclonal antibody for the treatment of early Alzheimer's disease: study design and baseline characteristics for a 96-week, multiple dose, randomized, double-blind, placebo-controlled phase 2 study[J]. Alzheimers Dement, 2018, 14(7s): P218-219.
[51]
CACABELOS R. How plausible is an Alzheimer's disease vaccine?[J]. Expert Opin Drug Discov, 2020, 15(1): 1-6.
[52]
LANE R M, KORDASIEWICA H B, SMITH A, et al. Discovery and early clinical development of Ionis-MAPTRx, the first tau-lowering antisense oligonucleotide, in patients with mild AD[J]. Alzheimers Dement, 2017, 13(7s): 600.
[53]
TSAI R M, MILLER Z, KOESTLER M, et al. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial[J]. JAMA Neurol, 2019, 77(2):215-224.
[54]
GAUTHIER S, FELDMAN H H, SCHNEIDER L S, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial[J]. Lancet, 2016, 388(10062): 2873-2884.
[55]
WILCOCK G K, GAUTHIER S, FRISONI G B, et al. Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: cohort analysis as modified primary outcome in a phase Ⅲ clinical trial[J]. J Alzheimers Dis, 2018, 61(1): 435-457.
[56]
HASHWEH N N, BARTOCHOWSKI Z, KHOURY R, et al. An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease[J]. Expert Opin Pharmacother, 2020, 21(6):619-627.
[57]
SCHELTER B O, SHIELLS H, BADDELEY T C, et al. Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer's disease[J]. J Alzheimers Dis, 2019, 72(3): 931-946.
[58]
MEDINA M. An overview on the clinical development of Tau-based therapeutics[J]. Int J Mol Sci, 2018, 19(4):1160.
[59]
WANG K R, LIU W M, SANG Z P. Progress of multi-target directed drugs based on tacrine and donepezil in Alzheimer's disease [J]. Chin Pharm J(中国药学杂志), 2019, 54(5):352-359.
[60]
CALHOUN A, KING C, KHOURY R, et al. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease[J]. Expert Opin Pharmacother, 2018, 19(15): 1711-1717.
[61]
FDA. Namzaric (memantine and donepezil hydrochlorides) extended-release capsules, for oral use[EB/OL]. [2016-07]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206439lbl.pdf.
[62]
GROSSBERG G T, MANES F, ALLEGRI R F, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors[J]. CNS Drugs, 2013, 27(6): 469-478.
[63]
GROSSBERG G, ALVA G, HENDRIX S, et al. Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial[J]. Alzheimers Dement, 2014, 10(4s): P450.
[64]
TAYLOR C P, TRAYNELIS S F, SIFFERT J, et al. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta) clinical use[J]. Pharmacol Ther, 2016, 164: 170-182.
[65]
CUMMINGS J L, LYKETSOS C G, PESKIND E R, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial[J]. JAMA, 2015, 314(12): 1242-1254.
[66]
NEWMAN J C, STEINMAN M A. Dextromethorphan-quinidine for agitation in Alzheimer disease[J]. JAMA, 2016, 315(11): 1166.
[67]
KONGPAKWATTANA K, SAWANGJIT R, TAWANKANJANACHOT I, et al. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network Meta-analysis[J]. Br J Clin Pharmacol, 2018, 84(7): 1445-1456.
[68]
SHI J Q, WANG B R, JIANG W W, et al. Cognitive improvement with intrathecal administration of infliximab in a woman with Alzheimer's disease[J]. J Am Geriatr Soc, 2011, 59(6): 1142-1144.
[69]
KIM D H, CHOI S M, JHO J, et al. Infliximab ameliorates AD-associated object recognition memory impairment[J]. Behav Brain Res, 2016, 311: 384-391.
[70]
TOBINICK E, GROSS H, WEINBERGER A, et al. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study[J]. Med Gen Med, 2006, 8(2): 25.
[71]
BUTCHART J, BROOK L, HOPKINS V, et al. Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial[J]. Neurology, 2015, 84(21): 2161-2168.
[72]
XINYI W, GUANGQIANG S, TENG F, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression[J]. Cell Res, 2019, 29(10):787-803.
[73]
SEO D O, BOROS B D, HOLTZMAN D M. The microbiome: a target for Alzheimer disease?[J]. Cell Res, 2019, 29(10): 779-780.
[74]
GAO Y, ZHANG L, JIAO W. Marine glycan-derived therapeutics in China[J]. Prog Mol Biol Transl Sci, 2019, 163: 113-134.
[75]
SHI-FU X. A 36-week multicenter,randomized,double-blind, placebo-controlled,parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer disease[J]. Chin J Pharm Toxicol(中国药理学与毒理学杂志), 2019, 33(6):403.
[76]
SYED Y Y. Sodium oligomannate: first approval[J]. Drugs, 2020, 80(4): 441-444.
[77]
IMFELD P, BODMER M, JICK S S, et al. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study[J]. J Am Geriatr Soc, 2012, 60(5): 916-921.
[78]
VANHERLE L, MATUSKOVA H, DON-DONCOW N, et al. Improving cerebrovascular function to increase neuronal recovery in neurodegeneration associated to cardiovascular disease[J]. Front Cell Dev Biol, 2020, 8: 53.
[79]
HSU C C, WAHLQVIST M L, LEE M S, et al. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin[J]. J Alzheimers Dis, 2011, 24(3): 485-493.
[80]
SHI Q, LIU S, FONSECA V A, et al. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus[J]. BMJ Open, 2019, 9(7): e024954.
[81]
SLUGGETT J K, KOPONEN M, BELL J S, et al. Metformin and risk of Alzheimer's disease among community-dwelling people with diabetes: a national case-control study[J]. J Clin Endocrinol Metab, 2019, 105(4):963-972.
[82]
MARKOWICZ-PIASECKA M, SIKORA J, SZYDLOWSKA A, et al. Metformin-a future therapy for neurodegenerative diseases: theme: drug discovery, development and delivery in Alzheimer's disease guest editor: davide brambilla[J]. Pharm Res, 2017, 34(12): 2614-2627.
[83]
CRAFT S, BAKER L D, MONTINE T J, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial[J]. Arch Neurol, 2012, 69(1): 29-38.
[84]
BIESSELS G J, VERHAGEN C, JANSSEN J, et al. Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial[J]. Diabetes Care, 2019, 42(10): 1930-1938.
[85]
FEMMINELLA G D, FRANGOU E, LOVE S B, et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)[J]. Trials, 2019, 20(1): 191.
[86]
HUANG W, LI Z, ZHAO L, et al. Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b[J]. Biomed Pharmacother, 2017, 92: 46-57.
[87]
ZHOU B, TERAMUKAI S, FUKUSHIMA M. Prevention and treatment of dementia or Alzheimer's disease by statins: a Meta-analysis[J]. Dement Geriatr Cogn Disord, 2007, 23(3): 194-201.
[88]
MCGUINNESS B, CRAIG D, BULLOCK R, et al. Statins for the prevention of dementia[J]. Cochrane Database Syst Rev, 2016, (1): Cd003160.
[89]
DAVIS K A S, BISHARA D, PERERA G, et al. Benefits and harms of statins in people with dementia: a systematic review and Meta-analysis[J]. J Am Geriatr Soc, 2020, 68(3): 650-658.
[90]
POWER M C, WEUVE J, SHARRETT A R, et al. Statins, cognition, and dementia-systematic review and methodological commentary[J]. Nat Rev Neurol, 2015, 11(4): 220-229.
[91]
ZISSIMOPOULOS J M, BARTHOLD D, BRINTON R D, et al. Sex and race differences in the association between statin use and the incidence of Alzheimer disease[J]. JAMA Neurol, 2017, 74(2): 225-232.
[92]
TROFIMIUK E, WIELGAT P, BRASZKO J J. Candesartan, angiotensin II type 1 receptor blocker is able to relieve age-related cognitive impairment[J]. Pharmacol Rep, 2018, 70(1): 87-92.
[93]
TORIKA N, ASRAF K, APTE R N, et al. Candesartan ameliorates brain inflammation associated with Alzheimer's disease[J]. CNS Neurosci Ther, 2018, 24(3): 231-242.
[94]
LAWLOR B, SEGURADO R, KENNELLY S, et al. Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial[J]. PLoS Med, 2018, 15(9): e1002660.
[95]
NOVOTNY M, KLIMOVA B, VALIS M. Nitrendipine and dementia: forgotten positive facts?[J]. Front Aging Neurosci, 2018, 10: 418.
[96]
SZABO-REED A N, VIDONI E, BINDER E F, et al. Rationale and methods for a multicenter clinical trial assessing exercise and intensive vascular risk reduction in preventing dementia (rrAD study)[J]. Contemp Clin Trials, 2019, 79: 44-54.
2020, Vol. 55 
